PMV Pharmaceuticals, Inc.: management transactions · United States · SEC (Form 4)

About PMV Pharmaceuticals, Inc.

PMV Pharmaceuticals, Inc. (ticker: PMVP) is a U.S.-based biotechnology company listed on the NASDAQ market in the United States, focused on precision oncology. The company is developing small-molecule therapies designed to target mutations in p53, one of the most important tumor-suppressor pathways in cancer biology. Its core scientific thesis is to restore the function of mutant p53 and thereby re-enable the body’s natural anti-cancer mechanisms. PMV Pharmaceuticals was founded in 2013 by David Mack, Ph.D., Arnold Levine, Ph.D., and Thomas Shenk, Ph.D., and is headquartered in Princeton, New Jersey. ([pmvpharma.com](https://www.pmvpharma.com/?utm_source=openai)) The company’s lead clinical program is rezatapopt, a candidate designed to address tumors carrying the TP53 Y220C mutation. PMV Pharma’s development strategy is built around a tumor-agnostic approach: the drug is intended to treat cancers defined by a genetic alteration rather than by the organ of origin. In recent disclosures, management indicated that it expects to submit an NDA for rezatapopt in platinum-resistant/refractory ovarian cancer in the first quarter of 2027, which places the asset in an advanced but still pre-commercial stage. Recent clinical and scientific milestones, including Phase 2 PYNNACLE interim data and a New England Journal of Medicine publication describing first-in-human data, have strengthened the company’s credibility and helped validate the scientific rationale behind its p53 platform. ([ir.pmvpharma.com](https://ir.pmvpharma.com/news-releases/news-release-details/pmv-pharmaceuticals-reports-full-year-2025-financial-results-and/?utm_source=openai)) From a competitive standpoint, PMV Pharmaceuticals occupies a highly specialized niche. Its differentiation comes from targeting mutant p53, a historically difficult drug target, and from focusing on a clearly defined molecular subset of patients with high unmet medical need. That focus can create meaningful upside if clinical and regulatory execution remains positive, but it also means the investment case is concentrated in a small number of programs and is therefore sensitive to trial readouts, regulatory timing, and financing needs. Recent full-year and quarterly updates indicate that PMV remains a clinical-stage biotech, with capital allocation and pipeline progression centered on rezatapopt and the broader p53 platform. ([ir.pmvpharma.com](https://ir.pmvpharma.com/news-releases/news-release-details/pmv-pharmaceuticals-reports-full-year-2025-financial-results-and/?utm_source=openai)) Geographically, PMV operates primarily from the United States, with its corporate and R&D activities centered in Princeton, New Jersey. The company also recently announced a board chair transition, underscoring an active governance phase as it advances toward key clinical and regulatory milestones. For investors in Europe seeking exposure to U.S. NASDAQ-listed biotech names, PMVP is a high-risk, high-potential precision-oncology story: scientifically differentiated, still execution-dependent, and closely tied to the outcome of rezatapopt development and eventual regulatory filing. ([ir.pmvpharma.com](https://ir.pmvpharma.com/news-releases/news-release-details/pmv-pharmaceuticals-announces-board-chair-transition/?utm_source=openai))